

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL HUMBER FILING DAYE FIRST NAMED INVESTOR INTERNATIONAL NO. 07/119,746 11/12/87 BOYSE 6287-003 EXAMINER PENNIE AND EDMONDS 1155 AVENUE OF THE AMERICAS NEW YORK, NY 10036 o∌ f€ .::Au.≥3: TO WITH UNIQUED CONTROL WITH STRUGGER CONTROL COME OF EDUCATION OF WITH CONTROL CONTROL 02/15/90 Responsive to communication filed on 12-26-89 This action is made final. A shortened statutory period for response to this action is set to expire. month(s), devs from the date of this letter Failure to respond within the period for response will cause the application to become abandoned. THE FOLLOWING ATTACHMENT(8) ARE PART OF THIS ACTION: 1. \square Notice of References Cited by Examiner, PTO-892. 2. Notice re Patent Drawing, PTO-948. 4. Notice of informal Patent Application, Form PTO-152. 5. \square information on How to Effect Drawing Changes, PTO-1474. 6. 🗆 **SUMMARY OF ACTION** Part II 1. Claims are pending in the application. 2. Claims. 3. Claims 4. Claims are objected to. are subject to restriction or election requirement. 7. This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes. 8. Formal drawings are required in response to this Office action. 9.

The corrected or substitute drawings have been received on ____ ... Under 37 C.F.R. 1.84 these drawings are \square acceptable. \square not acceptable (see explanation or Notice re Patent Drawing, PTO-948). 10. The proposed additional or substitute sheet(s) of drawings, filed on ______ ____ has (have) been 🔲 approved by the examiner.

disapproved by the examiner (see explanation). 11. The proposed drawing correction, filed on _____ _____, has been approved. disapproved (see explanation). 12. \square Acknowledgment is made of the claim for priority under U.S.C. 119. The certified copy has \square been received \square not been received been filed in parent application, serial no. _ ____ ; filed on . 13. \Box Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. 14. Other

EXAMINER'S ACTION

PTOL-326 (Rev. 6-88)

The claims in this application are 1-56.

Newly submitted claim 1-9 directed to an invention that is independent or distinct from the invention originally claimed for the following reasons:

The previously presented claims 1-9 involved two types of cells; the instantly presented claims are directed to a single cell and a cryopreservative.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits.

Accordingly, claim 1-9 withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP 821.03.

Applicant is given one month from the date of this action to reinstate claims directed to the originally elected invention.

State of the art: Rinfret et al is cited to show that it is conventional to add cryoprotectants to blood prior to freezing (col. 2); therefore it would be obvious to add cryoprotectants to hematopoietic stem cells prior to freezing following the teaching of Rinfret et al.

Rosen-rb

2-13-90

A/C 703-

557-0664

SAM ROSEN EXAMINER